Press Releases 2020

  • Liminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)

    Liminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)

    The FDA confirmed that the resubmission is a complete, Class 2 response and has provided a Prescription Drug User Fee Act ("PDUFA") target action date of March 5, 2021.

    Read Article
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Go To H.C. Wainwright 22nd Annual Global Investment Conference: Tuesday 15th September at 3:30-3:50 PM (EDT).

    View Now
  • Liminal Biosciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference

    Liminal Biosciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference

    LMNL announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at The H.C. Wainwright 22nd Annual Global Investment Conference

    Read Article
  • Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)

    Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)

    Liminal, through its U.S. subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the Biologics License Application (BLA) for Ryplazim® (plasminogen) (Ryplazim®) with the U.S. FDA

    Read Article
  • Liminal BioSciences Announces New Appointments to its Board of Directors

    Liminal BioSciences Announces New Appointments to its Board of Directors

    LMNL announced today the appointment of Mr. Alek Krstajic and Mr. Eugene Siklos to the Board of Directors, effective immediately.

    Read Article
  • Liminal BioSciences reports financial results for Q2-2020

    Liminal BioSciences reports financial results for Q2-2020

    Read Article
  • Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference

    Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference

    Liminal BioSciences is scheduled to present a company overview at Canaccord 40th Annual Growth Conference on Thursday 13th August 2:00-2:25 PM (EDT)

    Read Article
  • Liminal Biosciences to Voluntarily Delist from the Toronto Stock Exchange

    Liminal Biosciences to Voluntarily Delist from the Toronto Stock Exchange

    LMNL announces that it has applied for a voluntarily delisting of its common shares (“Common Shares”) from the Toronto Stock Exchange (“TSX”) in Canada.

    Read Article
  • Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases

    Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases

    Read Article
  • Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy

    Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy

    LMNL announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance.

    Read Article
  • Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors

    Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors

    LMNL today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences, has commenced the collection of convalescent plasma from donors who have recovered from COVID-19.

    Read Article
  • Liminal BioSciences Provides Guidance on Certain Expected Key Milestones For 2020

    Liminal BioSciences Provides Guidance on Certain Expected Key Milestones For 2020

    LMNL today provided a guidance update on the timing of certain expected key milestones for 2020

    Read Article
  • Liminal BioSciences to present at Raymond James Human Health Innovation Conference

    Liminal BioSciences to present at Raymond James Human Health Innovation Conference

    Liminal BioSciences to present at Raymond James Human Health Innovation Conference

    Read Article
  • Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting of Shareholders (AGM)

    Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting of Shareholders (AGM)

    Read Article
  • Liminal BioSciences to present at Jefferies Virtual Healthcare Conference

    Liminal BioSciences to present at Jefferies Virtual Healthcare Conference

    Liminal BioSciences to present at Jefferies Virtual Healthcare Conference 2020

    Read Article
  • Liminal BioSciences Reports Q1 2020 Results

    Liminal BioSciences Reports Q1 2020 Results

    Liminal BioSciences Reports Q1 2020 Results

    Read Article
  • Liminal BioSciences comments on Coronavirus (Covid-19)

    Liminal BioSciences comments on Coronavirus (Covid-19)

    LMNL commented today on the impact of the current COVID-19 pandemic on its operations

    Read Article
  • Liminal BioSciences reports fourth quarter and 2019 year end results

    Liminal BioSciences reports fourth quarter and 2019 year end results

    LMNL today reported its financial results for the fourth quarter and year-ended December 31, 2019.

    Read Article
  • Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast

    Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast

    LMNL announced today it will report its financial results for the fourth quarter and financial year ended December 31, 2019 on Friday March 20, 2020 after market close.

    Read Article
  • Liminal BioSciences announces scientific presentations at upcoming Keystone Symposia

    Liminal BioSciences announces scientific presentations at upcoming Keystone Symposia

    LMNL announced the Company and its collaborators will present scientific findings at two upcoming Keystone Symposia

    Read Article
  • Liminal BioSciences announces upcoming investor presentation at BIO CEO & investor conference

    Liminal BioSciences announces upcoming investor presentation at BIO CEO & investor conference

    Members of the management team will provide a business overview and update at the BIO CEO & Investor Conference taking place February 10-11, 2020 in New York, USA.

    Read Article
  • loading
    Loading More...